The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease

被引：424
|
作者：
Cookson, Mark R. [1 ]
机构：
[1] NIA, Neurogenet Lab, NIH, Bethesda, MD 20982 USA
来源：
NATURE REVIEWS NEUROSCIENCE | 2010年 / 11卷 / 12期
基金：
美国国家卫生研究院;
关键词：
AUTOSOMAL-DOMINANT PARKINSONISM; ALPHA-SYNUCLEIN; LEUCINE-RICH-REPEAT-KINASE-2; LRRK2; CYTOPLASMIC LOCALIZATION; 14-3-3; BINDING; ROC DOMAIN; MUTATIONS; PROTEIN; PHOSPHORYLATION; GENE;
D O I：
10.1038/nrn2935
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Parkinson's disease, like many common age-related conditions, is now recognized to have a substantial genetic component. Here, I discuss how mutations in a large complex gene-leucine-rich repeat kinase 2 (LRRK2) - affect protein function, and I review recent evidence that LRRK2 mutations affect pathways that involve other proteins that have been implicated in Parkinson's disease, specifically a-synuclein and tau. These concepts can be used to understand disease processes and to develop therapeutic opportunities for the treatment of Parkinson's disease.
引用
收藏
页码：791 / 797
页数：7
相关论文
共 50 条
  • [1] Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease
    Domingos, Sofia
    Duarte, Teresa
    Saraiva, Lucilia
    Guedes, Rita C.
    Moreira, Rui
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (15) : 1953 - 1977
  • [2] Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson's Disease
    Gilligan, Paul J.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2015, 15 (10) : 927 - 938
  • [3] Targeting leucine-rich repeat kinase 2 in Parkinson's disease
    Chan, Sharon L.
    Angeles, Dario C.
    Tan, Eng-King
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (12) : 1471 - 1482
  • [4] Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date
    Morez, Margaux
    Ordonez, Antonio Jesus Lara
    Melnyk, Patricia
    Liberelle, Maxime
    Lebegue, Nicolas
    Taymans, Jean-Marc
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2024, 34 (09) : 773 - 788
  • [5] Leucine-Rich Repeat Kinase 2 (LRRK2): A Key Player in the Pathogenesis of Parkinson's Disease
    Gandhi, Payal N.
    Chen, Shu G.
    Wilson-Delfosse, Amy L.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2009, 87 (06) : 1283 - 1295
  • [6] Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease
    Lee, Byoung Dae
    Dawson, Valina L.
    Dawson, Ted M.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (07) : 365 - 373
  • [7] Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease
    Bardien, Soraya
    Lesage, Suzanne
    Brice, Alexis
    Carr, Jonathan
    PARKINSONISM & RELATED DISORDERS, 2011, 17 (07) : 501 - 508
  • [8] Development of Inducible Leucine-rich Repeat Kinase 2 (LRRK2) Cell Lines for Therapeutics Development in Parkinson's Disease
    Huang, Liang
    Shimoji, Mika
    Wang, Juan
    Shah, Salim
    Kamila, Sukanta
    Biehl, Edward R.
    Lim, Seung
    Chang, Allison
    Maguire-Zeiss, Kathleen A.
    Su, Xiaomin
    Federoff, Howard J.
    NEUROTHERAPEUTICS, 2013, 10 (04) : 840 - 851
  • [9] Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond
    Bae, Jae Ryul
    Lee, Byoung Dae
    BMB REPORTS, 2015, 48 (05) : 243 - 248
  • [10] Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors
    Estrada, Anthony A.
    Sweeney, Zachary K.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (17) : 6733 - 6746
12345